Siloam Biosciences Receives a $1 million Phase II SBIR Contract to Develop an Immunodiagnostic System Using Only ¼ of a Drop of Blood for Cancer Tests

Cincinnati, OH – Siloam Biosciences, Inc., a privately held firm with a dramatically improved diagnostic platform using its advanced microfluidic Optimiser™ technology, entered into a two-year, $1 million contract with the National Cancer Institute (NCI) to develop a desktop instrument to test multiple cancer biomarkers using a fraction of a drop of blood, and 5… Read More Siloam Biosciences Receives a $1 million Phase II SBIR Contract to Develop an Immunodiagnostic System Using Only ¼ of a Drop of Blood for Cancer Tests